[exclusive] brief analysis of bidding dynamics in June 2018 (Pfizer 20 varieties applied for price reduction in Hubei, with a decrease of 3.4% - 10.2%)

In June 2018, Hubei, Guizhou, Jiangsu, etc are the trends that should be paid attention to in the provinces and cities The small edition summarized the trends of drug bidding in this month (June) and briefly analyzed some projects for reference (as of July 3): 1 Summary of bidding trends in various provinces and cities 2 Brief analysis On June 12, 2018, Ningxia issued a notice on canceling the qualification of 263 drug product specifications of some drug manufacturers, including 212 drug product specifications of non supply or abnormal supply, and 51 drug product specifications of drug manufacturers with inferior drug records Among them, there are 4 manufacturers with poor drug production records, including Hebei Tiancheng pharmaceutical, Shaanxi Hanwang pharmaceutical, Jilin Yizheng pharmaceutical and Tianfang pharmaceutical This month Jiangsu Haosen's bortezomib for injection issued a price reduction notice in Jiangsu and Guizhou The specific price reduction information is as follows: Table 1 price reduction information of Haosen is also worth paying attention to Pfizer, which has responded to the tax reform Hubei Province released 20 varieties of Pfizer's price reduction this month, with a price reduction of 3.4% - 10.2% Table 2 Pfizer lowered the catalogue of varieties on July 2, 2018 Gansu also issued a notice on adjusting the bid price of some drugs Xi'an YANGSEN Pharmaceutical Co., Ltd and Gansu heavy Pharmaceutical Co., Ltd also took the initiative to apply for price reduction of some varieties Table 3 Gansu reduced varieties catalogue if you need to know more about the bidding dynamics, please remember to pay attention to our pharmaceutical intelligence bid database Data source: yaozhi.com database note: the intellectual property rights of the above articles belong to yaozhi.com If you need to reprint, please indicate the source and the link of this article.